Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Establishment of phosphatidylinositol 3-kinase inhibitor-resistant cancer cell lines and therapeutic strategies for overcoming the resistance.

Cancer science - 1 Nov 2012

Isoyama Sho, Dan Shingo, Nishimura Yumiko, Nakamura Naoki, Kajiwara Gensei, Seki Mariko, Irimura Tatsuro, Yamori Takao

Abstract excerpt

Acquired resistance is a major obstacle for conventional cancer chemotherapy, and also for some of the targeted therapies approved to date. Long-term treatment using protein tyrosine kinase inhibitors (TKIs), such as gefitinib and imatinib, gives rise to resistant cancer cells carrying a drug-res...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Screening Assays, Antitumor

Share to Phosphatidylinositol 3-Kinases

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Proto-Oncogene Proteins c-akt

Share to Receptors, Somatomedin

Share to Triazines

Source

Open in PubMed Open full text

Identifiers

PMID: 22925034
DOI: 10.1111/cas.12004
PMCID: PMC7659208

Genes

BCR
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22925034-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Establishment of phosphatidylinositol 3-kinase inhibitor-resistant cancer cell lines and therapeutic strategies for overcoming the resistance.PMID 22925034Read ↗

The phosphoinositide 3-kinase pathway and therapy resistance in cancerSemantic proximity Read ↗

Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapySemantic proximity Read ↗

What a Tangled Web We Weave: Emerging Resistance Mechanisms to Inhibition of the Phosphoinositide 3-Kinase PathwaySemantic proximity Read ↗

Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular PlasticitySemantic proximity Read ↗

Overcoming resistance to tyrosine kinase inhibitors: Lessons learned from cancer cells treated with EGFR antagonistsSemantic proximity Read ↗

Resistance to tyrosine kinase inhibitors: calling on extra forces.Semantic proximity Read ↗

Targeting PI3Kα overcomes resistance to KRasG12C inhibitors mediated by activation of EGFR and/or IGF1R.Semantic proximity Read ↗

Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.Semantic proximity Read ↗

Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review).Semantic proximity Read ↗

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.Semantic proximity Read ↗

Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways.Semantic proximity Read ↗

Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.